EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles

Antje M Zickler iD, Xiuming Liang iD, Dhanu Gupta iD, Doste R Mamand, Mariacristina De Luca, Giulia Corso, Lorenzo Errichelli iD, Justin Hean, Titash Sen iD, Omnia M Elsharkasy, Noriyasu Kamei iD, Zheyu Niu und 8 weitere

Advanced Science · 2024-11 · 11 (42)

DOI: 10.1002/advs.202407619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.09.2024. Verfasst von Antje M Zickler und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, ANA Futura, Alfred-Nobels-Allé 8, Huddinge,…. Hauptthemen laut MEDLINE: Extracellular Vesicles, RNA, Messenger. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Innovative Medicine, Vetenskapsrådet, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) has emerged as an attractive therapeutic molecule for a plethora of clinical applications. For in vivo functionality, mRNA therapeutics require encapsulation into effective, stable, and safe delivery systems to protect the cargo from degradation and reduce immunogenicity. Here, a bioengineering platform for efficient mRNA loading and functional delivery using bionormal nanoparticles, extracellular vesicles (EVs), is established by expressing a highly specific RNA‐binding domain fused to CD63 in EV producer cells stably expressing the target mRNA. The additional combination with a fusogenic endosomal escape moiety, Vesicular Stomatitis Virus Glycoprotein, enables functional mRNA delivery in vivo at doses substantially lower than currently used clinically with synthetic lipid‐based nanoparticles. Importantly, the application of EVs loaded with effective cancer immunotherapy proves highly effective in an aggressive melanoma mouse model. This technology addresses substantial drawbacks currently associated with EV‐based nucleic acid delivery systems and is a leap forward to clinical EV applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesRNA, MessengerAnimalsMiceDisease Models, AnimalNanoparticlesBioengineeringHumansMelanoma

Stichwörter der Autor:innen

bioengineeringcancer immunotherapydrug deliveryextracellular vesiclesnanotechnologynucleic acid therapeutics

Substanzen

RNA, Messenger

Autor:innen und Institutionen

  • Division of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, ANA Futura, Alfred-Nobels-Allé 8, Huddinge, Stockholm, 14152, Sweden.
  • Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, 14186, Sweden.
  • Karolinska ATMP Center, Karolinska Institutet, ANA Futura, Alfred-Nobels-Allé 8, Huddinge, Stockholm, 14152, Sweden.
  • Cancer Research Laboratory, Shandong University-Karolinska Institutet collaborative Laboratory, School of Basic Medical Science, Shandong University, No. 44, Wenhua Xi Road, Ji'nan, Shandong, 250012, P. R. China.
  • Institute of Developmental and Regenerative Medicine, Department of Paediatrics., University of Oxford, Old Road Campus, Roosevelt Dr, Headington, Oxford, OX3 7TY, UK.
  • Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, 14186, Sweden.

ORCID-Profile: Antje M Zickler, Xiuming Liang, Dhanu Gupta, Lorenzo Errichelli, Titash Sen, Noriyasu Kamei, Samantha Roudi, Oscar P B Wiklander, André Görgens, Joel Z Nordin, Virginia Castilla-Llorente, Samir El Andaloussi

Förderung

  • Center for Innovative Medicine
  • Vetenskapsrådet
  • Cancerfonden
  • Stiftelsen för Strategisk Forskning
  • Horizon 2020 Framework Programme
  • HORIZON EUROPE European Research Council
  • Evox Therapeutics Ltd

Zitieren

APA

Zickler, A. M., Liang, X., Gupta, D., Mamand, D. R., De Luca, M., Corso, G., Errichelli, L., Hean, J., Sen, T., Elsharkasy, O. M., Kamei, N., Niu, Z., Zhou, G., Zhou, H., Roudi, S., Wiklander, O. P. B., Görgens, A., Nordin, J. Z., Castilla-Llorente, V., & El Andaloussi, S. (2024). Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles. Advanced Science, 11(42). https://doi.org/10.1002/advs.202407619

Vancouver

Zickler AM, Liang X, Gupta D, Mamand DR, De Luca M, Corso G, et al. Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles. Advanced Science. 2024;11(42). doi:10.1002/advs.202407619

BibTeX
@article{Zickler2024,
  author = {Zickler, Antje M and Liang, Xiuming and Gupta, Dhanu and Mamand, Doste R and De Luca, Mariacristina and Corso, Giulia and Errichelli, Lorenzo and Hean, Justin and Sen, Titash and Elsharkasy, Omnia M and Kamei, Noriyasu and Niu, Zheyu and Zhou, Guannan and Zhou, Houze and Roudi, Samantha and Wiklander, Oscar P B and Görgens, André and Nordin, Joel Z and Castilla-Llorente, Virginia and El Andaloussi, Samir},
  title = {Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {42},
  doi = {10.1002/advs.202407619}
}
Kostenlos starten →